Introduction
Long-acting opioids formulations have been used for treatment of moderate to severe chronic pain. Opana ER, a selective μ-opioid agonist made by Endo Pharmaceuticals, is an oral extended-release formulation of oxymorphone hydrochloride originally approved by US Food and Drug Administration (FDA) in 2006 for the treatment of chronic pain [1] . The first cases of thrombotic thrombocytopenic purpura (TTP) -mimicking illness associated with intravenous abuse of Opana ER were reported in 2012 in Tennessee, U.S.A. [2] . Despite warnings by FDA and CDC and release of a crush-resistant formulation of Opana by the drug maker, patients were still able to melt the tablets for intravenous abuse [3] [4] [5] [6] [7] [8] . TTP is a well-established cause of thrombotic microangiopathy (TMA) [9] . We report the first case of Opana induced thrombotic microangiopathy (TMA) involving both the kidney and the liver.
Case Report
A 34-year-old Caucasian female presented to the hospital emergency with headache, fatigue, mild abdominal pain, and dehydration over the past 4 days. Past medical history was notable for intravenous (IV) drug abuse and hepatitis. She admitted to active intravenous abuse of Opana ER, an extended release oral formulation
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Kurdi et al. Int J Pathol Clin Res 2016, 2:034 that was confirmed histologically. The term TMA was first described by Symmers [10] . TMA is characterized by thrombocytopenia, microangiopathic hemolytic anemia, occlusive microvascular thrombosis, and variable severity of end-organ damage [9, 11] . All features of TMA were present in our patient.
TTP and hemolytic uremic syndrome (HUS) are well-known primary causes of TMA. To a lesser extent, secondary TMA has been associated with infection, chemotherapy, disseminated malignancy, radiation, and toxins [12] . Drug-induced TMA is rare but associated with higher morbidity and mortality. Examples of such drugs include Mitomycin, Tacrolimus, Interferon, and Clopidogrel [9] . The first cases of TTP-like illnesses caused by intravenous abuse of Opana ER were reported by CDC in Tennessee in 2012 after state-wide investigation triggered by a nephrologist report to The Tennessee Department of Health of three cases of unexplained TTP [2] .
While more TTP-like cases secondary to IV administration of melted Opana ER tablets have been reported, histological studies on kidney biopsies from such cases have been very limited with no histological studies done on liver. Histological changes described in renal biopsies included interlobular arterial intimal edema and partial occlusion, loss of mesangial architecture, and ischemic changes in associated glomeruli [7, [13] [14] [15] [16] . This case of Opana IV abuse uniquely show evidence of histological findings of TMA in both the kidney and liver as shown in figure 1.
The patient in this Case Report had an acute infection secondary to chronic IV administration of melted Opana tablets and a history of hepatitis. Sepsis is usually associated with acute glomerulonephritis, which was ruled out. The histology of kidney biopsy showed evidence of TMA with moderate chronicity; finding more likely associated with chronic IV abuse of melted Opana ER tablets. Hepatitis is associated with general inflammatory changes. Although the scattered granulomata are non-specific and likely associated to the patient's history of IV drug abuse, there were vascular changes similar to those seen in the kidney biopsy, thus supporting TMA involvement of the liver.
After the report of two case fatalities due to Opana ER abuse in 2009 [13] , more focus was placed on how to improve the screening test for Opana ER as the widely available opiate immunoassays were poorly sensitive to this compound compared with the gas chromatography-mass spectrometry GC-MS. Lefebvre et al. found out that combination of DRI oxy assay and CEDIA Opi test was a good screening test to detect opiate, including oxymorphone, in urine [17] .
While therapeutic plasma exchange has been the main stay of therapy for Opana induced TMA, Miller et al. demonstrated in a case series that such treatment is unnecessary and supportive care and treatment of the underlying condition is key [16] . This may suggest that the effect of IV abuse of melted Opana ER on kidney and other organs is likely chemical or formulatory and less likely antibodymediated. Opana ER contains a hydrophilic matrix made of xanthan and locust bean gum. Oxymorphone is more lipid soluble than morphine due to a ketone-group substitution and more structurally related to hydromorphone. Its half-life via oral administration was prolonged in renal failure, while no information was established on its clearance and extraction from the liver [18] . The exact mechanism of how the IV abuse of melted Opana ER tablets, a sustained-release oral formulation, causes TMA is yet to be deciphered. Our patient did not receive the plasma exchange but did not finish the recommended course of treatment as she elected to leave the hospital prematurely.
Clinicians need to have high suspicion for Opana and similar IV drug abuse in a patient presenting with TTP-like illness. Diagnosing Opana-induced TMA is crucial since it is associated with increased mortality and hepatorenal pathology. . Of note, renal biopsy specimen contained 69 glomeruli in the tissue submitted for light microscopy, 23 glomeruli in the frozen tissue submitted for immunofluorescence, and 4 glomeruli in tissue submitted for electron microscopy. Of those, up to 4 glomeruli were globally sclerotic; the glomeruli with open capillary loops were slightly enlarged and appeared ischemic with wrinkled glomerular basement membrane. There were no glomerular proliferative lesions or cellular crescents in the biopsy specimen.
